| Disease | Hepatocellular carcinoma—HCC |
| Stage of disease/treatment | Locally advanced |
| Prior therapy | No designated number of regimens; no prior Y90 radioembolization permitted |
| Type of study | Pilot study, single arm |
| Primary endpoint | Progression-free survival at 6 months |
| Secondary endpoints | Time to progression, objective response rate, overall survival, safety/tolerability |
| Investigator’s analysis | Active and should be pursued further |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.